727 related articles for article (PubMed ID: 28787019)
1. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
[TBL] [Abstract][Full Text] [Related]
2. Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells.
Wang H; Vo T; Hajar A; Li S; Chen X; Parissenti AM; Brindley DN; Wang Z
BMC Cancer; 2014 Jan; 14():37. PubMed ID: 24447372
[TBL] [Abstract][Full Text] [Related]
3. Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers.
Wang R; Wang H; Wang Z
J Vis Exp; 2017 Feb; (120):. PubMed ID: 28287508
[TBL] [Abstract][Full Text] [Related]
4. Enhanced stability of microtubules contributes in the development of colchicine resistance in MCF-7 cells.
Rai A; Kapoor S; Naaz A; Kumar Santra M; Panda D
Biochem Pharmacol; 2017 May; 132():38-47. PubMed ID: 28242250
[TBL] [Abstract][Full Text] [Related]
5. Microtubule-binding natural products for cancer therapy.
Yue QX; Liu X; Guo DA
Planta Med; 2010 Aug; 76(11):1037-43. PubMed ID: 20577942
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of resistance to cabazitaxel.
Duran GE; Wang YC; Francisco EB; Rose JC; Martinez FJ; Coller J; Brassard D; Vrignaud P; Sikic BI
Mol Cancer Ther; 2015 Jan; 14(1):193-201. PubMed ID: 25416788
[TBL] [Abstract][Full Text] [Related]
7. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4.
Zhang CC; Yang JM; Bash-Babula J; White E; Murphy M; Levine AJ; Hait WN
Cancer Res; 1999 Aug; 59(15):3663-70. PubMed ID: 10446979
[TBL] [Abstract][Full Text] [Related]
8. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
Cai P; Lu P; Sharom FJ; Fang WS
Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826
[TBL] [Abstract][Full Text] [Related]
9. Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells.
Parekh H; Simpkins H
Cancer Chemother Pharmacol; 1996; 37(5):457-62. PubMed ID: 8599869
[TBL] [Abstract][Full Text] [Related]
10. Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents.
Tassone P; Blotta S; Palmieri C; Masciari S; Quaresima B; Montagna M; D'Andrea E; Eramo OP; Migale L; Costanzo F; Tagliaferri P; Venuta S
Int J Oncol; 2005 May; 26(5):1257-63. PubMed ID: 15809716
[TBL] [Abstract][Full Text] [Related]
11. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
Smiyun G; Azarenko O; Miller H; Rifkind A; LaPointe NE; Wilson L; Jordan MA
Cancer Chemother Pharmacol; 2017 Jul; 80(1):151-164. PubMed ID: 28567478
[TBL] [Abstract][Full Text] [Related]
12. New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer.
Zhang Y; Yang SH; Guo XL
Biomed Pharmacother; 2017 Dec; 96():659-666. PubMed ID: 29035832
[TBL] [Abstract][Full Text] [Related]
13. Targeting of tubulin polymerization and induction of mitotic blockage by Methyl 2-(5-fluoro-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-carboxylate (MBIC) in human cervical cancer HeLa cell.
Hasanpourghadi M; Karthikeyan C; Pandurangan AK; Looi CY; Trivedi P; Kobayashi K; Tanaka K; Wong WF; Mustafa MR
J Exp Clin Cancer Res; 2016 Mar; 35():58. PubMed ID: 27030360
[TBL] [Abstract][Full Text] [Related]
14. Triazolopyrimidines Are Microtubule-Stabilizing Agents that Bind the Vinca Inhibitor Site of Tubulin.
Sáez-Calvo G; Sharma A; Balaguer FA; Barasoain I; Rodríguez-Salarichs J; Olieric N; Muñoz-Hernández H; Berbís MÁ; Wendeborn S; Peñalva MA; Matesanz R; Canales Á; Prota AE; Jímenez-Barbero J; Andreu JM; Lamberth C; Steinmetz MO; Díaz JF
Cell Chem Biol; 2017 Jun; 24(6):737-750.e6. PubMed ID: 28579361
[TBL] [Abstract][Full Text] [Related]
15. Hypermethylation of the ABCB1 downstream gene promoter accompanies ABCB1 gene amplification and increased expression in docetaxel-resistant MCF-7 breast tumor cells.
Reed K; Hembruff SL; Laberge ML; Villeneuve DJ; Côté GB; Parissenti AM
Epigenetics; 2008 Sep; 3(5):270-80. PubMed ID: 19001875
[TBL] [Abstract][Full Text] [Related]
16. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
Tangutur AD; Kumar D; Krishna KV; Kantevari S
Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
[TBL] [Abstract][Full Text] [Related]
17. Kinase shRNA screening reveals that TAOK3 enhances microtubule-targeted drug resistance of breast cancer cells via the NF-κB signaling pathway.
Lai TC; Fang CY; Jan YH; Hsieh HL; Yang YF; Liu CY; Chang PM; Hsiao M
Cell Commun Signal; 2020 Oct; 18(1):164. PubMed ID: 33087151
[TBL] [Abstract][Full Text] [Related]
18. Interactions of microtubule-active agents with nicotinic acetylcholine receptors. Relationship to their inhibition of catecholamine secretion by adrenal chromaffin cells.
McKay DB; Aronstam RS; Schneider AS
Mol Pharmacol; 1985 Jul; 28(1):10-6. PubMed ID: 2410767
[TBL] [Abstract][Full Text] [Related]
19. A novel taxane, difluorovinyl-ortataxel, effectively overcomes paclitaxel-resistance in breast cancer cells.
Rong D; Wang C; Zhang X; Wei Y; Zhang M; Liu D; Farhan H; Momen Ali SA; Liu Y; Taouil A; Guo W; Wang Y; Ojima I; Yang S; Wang H
Cancer Lett; 2020 Oct; 491():36-49. PubMed ID: 32730778
[TBL] [Abstract][Full Text] [Related]
20. Tubulin Proteins in Cancer Resistance: A Review.
Kamal MA; Al-Zahrani MH; Khan SH; Khan MH; Al-Subhi HA; Kuerban A; Aslam M; Al-Abbasi FA; Anwar F
Curr Drug Metab; 2020; 21(3):178-185. PubMed ID: 32101117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
